The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 797-802

  Tillmann, Hans Ludger ^a,b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Adefovir; Almefovir; Antiviral therapy; Hepatitis B; Pradefovir; Tenofovir

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ENTECAVIR; LAMIVUDINE; PLACEBO; PRADEFOVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; LIVER; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; VIRUS LOAD;

EID: 52949083548     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Aus dem Siepen M, Oniangue-Ndza C, Wiese M, et al. 2007. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon. Virus Res, 125:109-13.
2. Berggren S, Gall C, Wollnitz N, et al. 2007. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm, 4:252-7.
3. Chan C, Abu-Raddad E, Golor G, et al. 2005. Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrob Agents Chemother, 49:1813-22.
4. Chang TT, Gish RG, de Man R, et al. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354:1001-10.
5. Chen CJ, Yang HI, Su J, et al. 2006. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295:65-73.
6. Choi JR, Cho DG, Roh KY, et al. 2004. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. J Med Chem, 47:2864-9.
7. Colonno RJ, Rose RE, Pokornowski K, et al. 2006. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology, 44:229-30.
8. Cornberg M, Protzer U, Dollinger MM, et al. 2007. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV) infection: upgrade of the guideline. AWMF-Register 021/011. Z Gastroenterol, 45:1287-328.
9. De Clercq E. 2007. Anti-HIV drugs. Verh K Acad Geneeskd Belg, 69:81-104.
10. de Franchis R, Hadengue A, Lan G, et al; EASL Jury. 2003. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002.
11. Geneva, Switzerland. Consensus statement. J Hepatol, 39:3-25.
12. Del Poggio P, Zaccanelli M, Oggionni M, et al. 2007. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J Gastroenterol, 13:4096-9.
13. Dienstag JL, Schiff ER, Wright TL, et al. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 341:1256-63.
14. Gilead. 2007a. Phase III Study evaluating Gilead's Viread® for the treatment of chronic hepatitis B virus meets primary endpoint [online]. Accessed on May 28, 2008. URL:http://www.gilead.com/wt/sec/pr_1012569.
15. Gilead. 2007b. Second Phase III Study evaluating Gilead's Viread® for the treatment of chronic hepatitis B virus meets primary endpoint [online]. Accessed on May 28, 2008. URL:http://www.gilead.com/wt/sec/ pr_1018988.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 348:800-7.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 352:2673-81.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 131:1743-51.
19. Han S, Lai C, Gane EJ, et al. 2007. Telbivudine globe trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B. Gastroenterology, 132:765.
20. Heathcote EJ, Gane E, De Man R, et al. A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) Versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007: (Suppl. 1) 231A.
21. Heathcote EJ, George J, Gordon S, et al. Tenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: Week 72 TDF data and week 24 Adefvoir Dipivoxil switch data (Study 103). J Hepatol 2008: (Suppl.2) S32.
22. Hezode C, Chevaliez S, Bouvier-Alias M, et al. 2007. Efficacy and safety of adefovir dipivoxil 20 ing daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol, 46:791-6.
23. Iloeje UH, Yang HI, Su J, et al; Risk Evaluation of Viral Load Elevation and Associated Liver Diseage/Cancer-In HBV (the REVEAL-HBV) Study Group. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 130:678-86.
24. Izzedine H, Hulot JS, Launay-Vacher V, et al. 2004. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int, 66:1153-8.
25. Jacquard AC, Brunelle MN, Pichoud C, et al. 2006. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother, 50:955-61.
26. Kahn J, Lagakos S, Wulfsohn M, et al. 1999. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA, 24:2305-12.
27. Lai CL, Shouval D, Lok AS, et al. 2006a. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354:1011-20.
28. Lai CL, Han KH, Yoon SK, et al. 2006b. Phase II, multi-centre, dose-escalating study of LB8030 (ANA380) in hepatitis B patients with lamivudine resistant YMDD mutant HBV. J Hepatol, 44:5.
29. Lau GK, Piratvisuth T, Luo KX, et al. 2005. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352:2682-95.
30. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11:97-107.
31. Lee KS, Lim SG, Chuang WL, et al. 2006. Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study. J Hepatol, 44:274.
32. Liaw YF, Leung N, Guan R, et al; Asian-Pacific Consensus Update Working Party on Chronic Hepatitis B. 2005. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int, 25:472-89.
33. Liaw YF, Sung JJ, Chow WC, et al; Cirrhosis Asian Lamivudine Multicentre Study Group. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521-31.
34. Lin C, Xu C, Yeh LT, et al. 2006. Pharmacokinetics and pharmacodynamics of pradefovir mesylate, a liver-targeting pro-drug of PMEA, in HBV patients. J Hepatol, 44:16.
35. Lin CC, Yeh LT, Vitarella D, et al. 2004. Remofovir mesylate: A prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antivir Chem Chemother, 15:307-17.
36. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology, 45:507-39.
37. Marcellin P, Chang TT, Lim SG, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348:808-16.
38. Marcellin P, Lau GK, Bonino F, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 351:1206-17.
39. Marcellin P, Buti M, Krastev Z, et al. A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102 Hepatology 2007: (Suppl. 1) 231A.
40. Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: Week 72 TDF data and week 24 Adefvoir Dipivoxil switch data (Study 102). J Hepatol 2008: (Suppl.2) S26.
41. McMahon MA, Jilek BL, Brennan TP, et al. 2007. The HBV drug entecavir- effects on HIV-1 replication and resistance. N Engl J Med, 356:2614-21.
42. Perz JF, Armstrong GL, Farrington LA, et al. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45:529-38.
43. Peters MG, Andersen J, Lynch P, et al. 2006. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology, 44:1110-6.
44. Röling J, Schmid H, Fischereder M, et al. 2006. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis, 42:1488-95.
45. Sheldon J, Camino N, Rodes B, et al. 2005. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 10:727-34.
46. Soon DK, Lowe SL, Teng CH, et al. 2004. Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol, 41:852-8.
47. Thio CL, Locarnini S. 2007. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev, 9:40-53.
48. Tillmann HL. 2007. Drug evaluation: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs, 8:682-90
49. van Bommel F, Berg T. 2005. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology, 42:239-40.
50. van Bommel F, Wunsche T, Mauss S, et al. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40:1421-5.
51. van Bommel F, Zollner B, Sarrazin C, et al. 2006. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 44:318-25.
52. van der Poorten D, Prakoso E, Khoo TL, et al. 2007. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol, 22:1500-5.
53. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. 2005. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther, 10:625-33.
54. You J, Zhuang L, Cheng HY, et al. 2006. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol, 12:6715-21.
55. Yuen MF, Kim J, Kim CR, et al. 2006. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther, 11:977-83.